R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)
Paolo Anderlini,Rima M. Saliba,Celina Ledesma,Christina Chancoco,Tamera R. Alexander,Amin M. Alousi,Chitra Hosing,Issa F. Khouri,Yago Nieto,Uday R. Popat,Elizabeth J. Shpall,Michelle A. Fanale,Yasuhiro Oki,Jorge E. Romaguera,Sattva S. Neelapu,Anas Younes,Richard E. Champlin +16 more
TL;DR: G-associated non-hematologic toxicities include pulmonary, skin toxicities and mucositis, and chimerism studies indicate 100% donor-derived engraftment in 23/23 evaluable patients (100%).
Journal ArticleDOI
Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center
Sai Ravi Pingali,Denái R. Milton,Antonio Di Stasi,Rushang D. Patel,Partow Kebriaei,Uday R. Popat,Amin M. Alousi,Paolo Anderlini,Muzaffar H. Qazilbash,Chitra Hosing,Katy Rezvani,Qaiser Bashir,Betul Oran,Elizabeth J. Shpall,Issa F. Khouri,Richard E. Champlin,Stefan O. Ciurea +16 more
Journal ArticleDOI
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant
M. de Lima,K. Van Besien,James Gajewski,Issa F. Khouri,Borje S. Andersson,M. Korbling,Richard E. Champlin,Sergio Giralt +7 more
TL;DR: This treatment produced responses in the majority of this poor prognosis group, however, durable remissions were not observed, and new treatments to consolidate the responses achieved in this setting are needed.
Journal ArticleDOI
Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.
Philip A. Thompson,Francesco C. Stingo,Michael J. Keating,William G. Wierda,Susan O'Brien,Zeev Estrov,Celina Ledesma,Katayoun Rezvani,Muzaffar H. Qazilbash,Nina Shah,Simrit Parmar,Uday R. Popat,Paolo Anderlini,Nieto Yago,Stefan O. Ciurea,Partow Kebriaei,Richard E. Champlin,Elizabeth J. Shpall,Chitra Hosing +18 more
TL;DR: Relapsed patients with mixed Chimerism had inferior response to immunomodulation; conversion to full donor chimerism was highly correlated both with CR and with the development of severe acute GVHD, which was fatal in 3/8 patients.
Journal ArticleDOI
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
Yago Nieto,Nizar M. Tannir,Shi-Ming Tu,Roy B. Jones,Amado J. Zurita,Ana Aparicio,Roland L. Bassett,Kim Margolin,Leona Holmberg,Richard E. Champlin,Lance C. Pagliaro +10 more
TL;DR: This data indicates that concurrent BEV/HDC in refractory GCT with high VEGF expression in metastatic GCT and synergy between BEV and chemotherapy, and no contraindications to HDC or BEV, poses a low risk of adverse events to patients.